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Abstract
Obsessive-compulsive disorder (OCD) and Tourette Syndrome (TS) are highly heritable 
neurodevelopmental disorders that are thought to share genetic risk factors. However, the 
identification of definitive susceptibility genes for these etiologically complex disorders remains 
elusive. Here, we report a combined genome-wide association study (GWAS) of TS and OCD in 
2723 cases (1310 with OCD, 834 with TS, 579 with OCD plus TS/chronic tics (CT)), 5667 
ancestry-matched controls, and 290 OCD parent-child trios. Although no individual single 
nucleotide polymorphisms (SNPs) achieved genome-wide significance, the GWAS signals were 
enriched for SNPs strongly associated with variations in brain gene expression levels, i.e. 
expression quantitative loci (eQTLs), suggesting the presence of true functional variants that 
contribute to risk of these disorders. Polygenic score analyses identified a significant polygenic 
component for OCD (p=2×10−4), predicting 3.2% of the phenotypic variance in an independent 
data set. In contrast, TS had a smaller, non-significant polygenic component, predicting only 0.6% 
of the phenotypic variance (p=0.06). No significant polygenic signal was detected across the two 
disorders, although the sample is likely underpowered to detect a modest shared signal. 
Furthermore, the OCD polygenic signal was significantly attenuated when cases with both OCD 
and TS/CT were included in the analysis (p=0.01). Previous work has shown that TS and OCD 
have some degree of shared genetic variation. However, the data from this study suggest that there 
are also distinct components to the genetic architectures of TS and OCD. Furthermore, OCD with 
co-occurring TS/CT may have different underlying genetic susceptibility compared to OCD alone.
INTRODUCTION
Obsessive-compulsive disorder (OCD) [MIM 164230] and Tourette Syndrome (TS) [MIM 
137580] are highly familial neuropsychiatric disorders with complex overlapping genetic 
etiologies (1–3). 20–60% of TS-affected individuals have co-occurring OCD, and 10–20% 
of those initially diagnosed with OCD have TS or chronic tics (CT), well over what is 
expected based on their respective population prevalences (4–6). Both disorders are 
characterized by the presence of repetitive, ritualized or stereotyped behaviors (tics and 
compulsions), often preceded by cognitive or sensory phenomena (premonitory urges and 
obsessions), and clinical differentiation of compulsions versus complex tics can be 
challenging (7). Genetic epidemiological studies suggest up to 90% shared genetic variance 
between TS/CT and OCD (8–10), and abnormalities in cortico-striatal-thalamo-cortical 
(CSTC) circuitry have been identified in both conditions (1).
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focused on candidate gene studies and linkage analyses; a few studies examining 
chromosome abnormalities and copy number variants (CNVs) have also been reported (11–
14). Recently, our group performed genome-wide association studies (GWAS) of TS and 
OCD, and for each disorder identified a number of genes and genomic regions of interest, 
most with modest significance levels. Here we report GWAS results for a combined sample 
of individuals with TS, OCD or TS+OCD, along with analyses aimed at elucidating the 
genetic architectures and genetic relationships between the two disorders. Combining these 
heterogeneous but related phenotypes in joint analyses could have one of two potential 
effects: 1) enhancement of the genetic signal as a consequence of increased power due to 
adding samples from genetically-related phenotypes; 2) reduction of the genetic signal as a 
consequence of increased genetic heterogeneity, outweighing potential benefits of increased 
sample size. Either way, given the prior evidence supporting shared genetic factors, and the 
lack of definitive susceptibility genes for either disorder, joint analyses of TS and OCD 
cases represent an important advance toward understanding the underlying causes of these 
common neuropsychiatric disorders.
MATERIALS AND METHODS
Cases
Individuals with TS or OCD were recruited as part of collaborative efforts to conduct the 
first GWAS for these disorders (details in Scharf et al, 2013; Stewart et al, 2013) (15, 16). 
Although data were collected independently for TS and OCD, all genotyping and data 
cleaning were done together, facilitating joint analyses. Participants ≥18 years of age 
provided written, voluntary informed consent. Individuals under 18 years of age provided 
assent; written parental consent for their participation was also obtained. The study was 
approved by the Ethics Committees of all participating sites and in accordance with the 
Declaration of Helsinki. For the cross-disorder analyses, any subject with either TS or OCD 
was considered affected. See Supplementary Methods for details of the inclusion and 
exclusion criteria and assessment protocols.
TS—The TS sample consisted of 1286 individuals recruited from 20 sites in the US, 
Canada, UK, Netherlands, and Israel, and included subjects of general European (EU) 
ancestry as well as two EU-derived population isolates of Ashkenazi Jewish (AJ) and French 
Canadian (FC) descent. Co-occurring OCD symptoms were assessed in 77% of participants; 
46% of those evaluated had co-occurring OCD (N=452). OCD status was unknown for 300 
individuals with TS.
OCD—The OCD sample consisted of 1,437 OCD cases and 290 parent-child trios. While 
the original GWAS sample consisted of 1865 OCD probands recruited from 21 sites in 
North, Central and South America, Europe, the United Arab Emirates, and South Africa, 
only subjects of European ancestry (EU, AJ, and EU-derived Afrikaner (SA) descent) were 
included in the current study (16). Co-occurring TS or CT was assessed in 77% of OCD 
probands; of these, 12% had co-morbid TS or CT (N=159). TS/CT status was unknown for 
405 OCD-affected individuals.
Yu et al. Page 3
Am J Psychiatry. Author manuscript; available in PMC 2016 January 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Controls
The EU control sample consisted of 4975 European Caucasian controls primarily derived 
from cohorts of previously genotyped, unselected population controls (Supplementary 
Methods). Ancestry-matched controls for the FC (N=196) and SA (N=158) samples were 
collected in parallel with their respective cases (15, 16). Ancestry-matched controls for 
individuals with AJ ancestry were identified from the EU control sample based on self-
reported ancestry and principal component analysis (N=338).
Genotyping and Quality Control (QC)
Genotyping and quality control procedures have been described previously (15,16, and 
Supplementary Methods). Briefly, cases and trios with TS or OCD and controls were 
randomized across plates and genotyped on the Illumina HumanHap610 SNP array 
(Illumina, San Diego, CA) at the Broad Institute of Harvard-MIT (Cambridge, MA) or on 
the Illumina HumanHap370 at the Yale Center for Genome Analysis (New Haven, CT) 
(Supplementary Figure S1). Eighty-eight samples were genotyped on both platforms to 
allow for cross-platform concordance checks. QC analyses were performed using PLINK 
v1.07(17) and EIGENSTRAT(18). Multi-dimensional scaling (MDS) analysis was used to 
exclude case-control samples of non-European descent. Remaining EU and European-
derived isolate samples were separated into four strata (EU, AJ, FC, and SA) based on 
observed genetic ancestry (15, 16). Imputation was performed using 1000 Genomes Project 
data (June 2011 Data Release)(19) as the reference panel using IMPUTE v2.1.2(20) 
(Supplementary Methods).
Genome-Wide Association Analyses
Individual ancestry-stratified case-control genome-wide association analyses (EU, AJ, FC, 
and SA) and one case/pseudo-control analysis using the OCD trios were performed in 
PLINK (17) using logistic regression under an additive model with significant 
subpopulation-specific MDS axes included as covariates to control for residual population 
stratification (Figure S2). These population-specific analyses were then combined in a fixed-
effects model meta-analysis using case-weighting in METAL (21). SNPs with p-values 
<10−5 were annotated with details including their genomic region and location, allele 
frequencies, nearby genes and p-values from individual TS and OCD GWAS studies. 
Heterogeneity tests were also conducted to assess subpopulation differences using 
Cochran’s Q and I2 statistics. As is standard in GWAS for complex traits, a genome-wide 
threshold of p<5×10−8 was considered statistically significant evidence of association (22, 
23).
Enrichment analyses
GWAS results were examined for enrichment of functional SNPs previously associated with 
gene expression levels in several brain regions (i.e., expression quantitative trait locus SNPs, 
eQTLs) or with variation in gene methylation levels (methylation QTLs, mQTLs). eQTL 
data were generated from cerebellum, parietal, and frontal cortex (Supplementary Methods). 
mQTLs were derived from adult cerebellum (24). Only GWAS SNPs meeting high 
stringency criteria for eQTLs or mQTLs (p<10−6) were considered. For each phenotype (TS, 
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OCD, combined), a quantile-quantile (Q-Q) plot of GWAS disease association p-values was 
generated for eQTL and mQTL SNPs and compared to a standard Q-Q plot of GWAS p-
values expected under the null assuming no enrichment. A leftward shift in the eQTL/mQTL 
Q-Q plot relative to the diagonal line (representing the null distribution) indicates 
enrichment of eQTLs/mQTLs. The level of enrichment of eQTLs or mQTLs in each brain 
tissue associated with TS or OCD was then quantified using a false discovery rate (FDR) of 
<0.25, i.e., 75% of observed SNPs represent true disease associations (Supplementary 
Methods).
Polygenic score analysis
Polygenic score analyses were conducted in PLINK using genotyped SNPs to test the 
hypothesis that multiple genes of small effect jointly contribute to TS and OCD 
susceptibility and to explore the genetic relationships between these disorders(25). Samples 
were divided into non-overlapping discovery and target samples (Supplementary Methods). 
For the primary OCD polygenic analysis, cases were restricted to subjects without known 
co-occurring TS/CT (OCD - TS/CT). SNPs with GWAS p-values passing pre-determined 
significance thresholds (p<0.01, 0.1, 0.2, 0.3, 0.4, and 0.5, respectively) in the discovery 
sample were extracted along with their risk alleles and odds ratios, and then LD pruned 
(r2<0.5). For each significance threshold, a quantitative aggregate risk score was calculated 
for each individual in the target sample, defined as the sum of the number of risk alleles 
present at each locus weighted by the log of the odds ratio for that locus estimated from the 
discovery sample. The relationship between aggregate risk score and case-control status in 
the target sample was examined at each significance threshold using logistic regression. The 
percentage of phenotypic variance explained by the aggregate risk score (Nagelkerke’s 
pseudo-R2) was estimated.
Two separate statistical approaches were used to determine the significance of the observed 
differences in polygenic risk score prediction between discovery samples. First, permutation 
testing was conducted to derive an empirical significance of the magnitude of change in R2 
between polygenic risk scores derived from the OCD - TS/CT discovery sample compared 
to those derived from the “All OCD” sample (OCD +/− TS/CT). Second, risk alleles from 
each discovery sample were used to calculate the difference in polygenic risk scores 
between the transmitted (case) alleles and the untransmitted (pseudo-control) alleles in the 
OCD Trio target sample. The degree of risk score elevation (Risk Scoretransmitted − Risk 
Scoreuntransmitted) was then standardized ([RStrans−RSuntrans]/RSuntrans), and compared 
between different discovery samples using two-sided paired t-tests. See Supplementary 
Methods for further details of both approaches.
RESULTS
Combined TS/OCD GWAS
The final combined TS/OCD dataset consisted of 2723 cases (1310 with OCD, 834 with TS, 
579 with OCD+TS/CT), 5667 controls, and 290 OCD trios. A total of 7,659,573 SNPs 
(439,840 genotyped and 7,219,733 imputed) were included in the meta-analysis. The 
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genomic control λ showed no evidence of residual population stratification or systematic 
technical artifacts (λGC=1.030; Figure S3).
Sixty-eight SNPs with p<1×10−5, representing 16 independent genomic regions, were 
identified, though none reached the genome-wide significance threshold of p<5×10−8 (Table 
1,Figure 1; Table S1). The most significant association was found in rs4988462 on 3p11 
(p=3.72×10−7, OR=1.18). This SNP lies within an intron of POU1F1, though the entire 279 
kb region of association in linkage disequilibrium (LD) with rs4988462 contains 16 
additional SNPs with p<1×10−5 and includes CHMP2B and POU1F1, as well as the 
microRNA MIR4795. Regional association and forest plots from the top five independent 
GWAS signals are provided in Figures S4–S8. Eleven of the 68 SNPs were also identified in 
the original OCD GWAS with p<1×10−5; none of these SNPs were identified in the TS 
GWAS at p<1×10−5 (15, 16) (Table S1).
Enrichment analyses
For TS, OCD, and the combined sample, we examined the subset of disease association p-
values for SNPs meeting stringent criteria for eQTLs (peQTL<10−6) derived from 
cerebellum, parietal cortex and frontal cortex, as well as cerebellar mQTLs (pmQTL<10−6) 
(Figure 2). Using the field standard FDR threshold of <0.25, we identified 38 cerebellar 
eQTLs from five LD-independent loci for TS, 161 cerebellar mQTLs (19 LD-independent 
loci) for OCD, and 53 parietal cortex eQTLs (four LD-independent loci) for the combined 
GWAS (Table 2).
Polygenic risk score analysis
Polygenic score analyses were conducted to test two related hypotheses: 1) that both TS and 
OCD individually harbor multiple, small effect, common risk alleles across the genome; 2) 
that TS and OCD may have shared common risk alleles (cross-disorder analyses). In the 
individual disorder analyses, risk scores derived from the “OCD - TS/CT” discovery sample 
strongly predicted case-control status in the OCD target sample (p=2.1×10−4), explaining 
3.2% of the phenotypic variance (Figure 3, Table S3). In contrast, risk scores derived from 
the TS discovery sample demonstrated only weak prediction in the TS target sample 
(p=0.06; R2=0.6% variance explained). Risk scores derived from the combined TS/OCD 
discovery sample also predicted case-control status in the OCD target sample (p=0.0075, 
R2=1.7%), though less robustly than those derived from the OCD discovery sample alone 
(p=0.01, Figure 3, inset). Risk scores derived from the TS/OCD combined sample could not 
discriminate between cases and controls in the TS target sample (p=0.4, Figure 3, Table S3).
In cross-disorder analyses, risk scores derived from the TS discovery sample did not predict 
case-control status in the OCD target sample (p=0.66), nor did OCD-associated risk scores 
predict into the TS target sample (p=0.37) (Figure 3, Table S3).
To explore the influence of phenotype co-morbidity on polygenic risk score prediction, an 
additional “All OCD” discovery sample was created which included the primary OCD 
discovery sample plus 345 additional cases with OCD + TS/CT. As expected, the polygenic 
score using risk alleles derived from this discovery sample predicted case-control status in 
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the OCD target sample (p=2.3×10−3) (Figure 3). However, the proportion of variance 
explained by the “All OCD” risk score was significantly attenuated compared to the risk 
score derived from the primary “OCD - TS/CT” discovery sample, despite the 30% increase 
in sample size (“OCD - TS/CT”, n=1154, R2=3.2%; “All OCD”, n=1499, R2=2.1%; 
permutation p=0.01, Figures 3 and S9).
In addition, the magnitude of elevation in the polygenic risk scores (risk score elevation) 
between transmitted risk alleles and untransmitted non-risk alleles in the OCD trios was 
calculated using risk alleles from the different OCD discovery samples and compared 
(Figure 3, inset). The risk score elevation in the OCD trios was highest when the primary 
“OCD - TS/CT” discovery sample was used to derive the risk score compared either to the 
“All OCD” sample or the combined TS/OCD sample (paired t-test; p=0.022 and p=0.010, 
respectively), consistent with a dilution of risk when either OCD cases with TS/CT or TS 
cases without OCD were incorporated in the discovery sample.
DISCUSSION
The goal of this study was to leverage phenotypic and genotypic data of two phenotypically-
related and frequently co-occurring neurodevelopmental disorders, TS and OCD, to explore 
the hypothesis that these disorders share common genetic susceptibility variants by: 1) 
combining the samples in a joint GWAS, 2) examining their patterns of eQTL/mQTL 
enrichment, and 3) exploring cross-disorder polygenic signals. Although limited by small 
sample sizes, the results of these diverse analytic approaches suggest a complex genetic 
relationship between TS and OCD.
While our previous work in this sample provides evidence of genetic sharing between TS 
and OCD, with a genetic correlation of 0.41 between the two disorders (10), we did not 
identify any genome-wide significant variants for the combined TS/OCD phenotype in this 
GWAS analysis, despite the increase in sample size. However, the combined GWAS signals 
were significantly enriched for functional alleles (parietal eQTLs), suggesting that these 
subthreshold variants contain some proportion of TS/OCD risk loci that are not simply due 
to stochastic variation. In the presence of genetic heterogeneity (see below), the current 
sample is underpowered to determine whether these loci contribute to both TS and OCD 
susceptibility, or to one or the other individually. As with any genetic association result, 
replication in an independent sample is required to know whether any of the individual 
eQTLs identified here are truly shared TS/OCD susceptibility variants (9, 26, 27).
However, the results of the polygenic analyses do provide strong evidence that OCD and TS 
have at least some distinct genetic risk factors. First, the individual disorder analyses 
confirm that OCD has a significant polygenic component. The proportion of OCD variance 
explained by directly interrogated SNPs (3.2%) is similar to the findings in schizophrenia 
(3–6%) and bipolar disorder (2.8%)(25), indicating that OCD likely arises from the joint 
influence of a large number of susceptibility genes spread across the genome, either as 
common variants or as rare variants in tight linkage disequilibrium with GWAS SNPs. This 
result is consistent with a parallel heritability study of the same datasets using mixed linear 
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modeling which found that OCD heritability is concentrated in common variants with minor 
allele frequencies (MAF)>30% (10).
In contrast, the proportion of TS variance explained was substantially lower (0.6%). 
Although some of the difference in polygenic risk prediction between OCD and TS may be 
due to the smaller discovery sample size for TS, a sensitivity analysis in which the OCD 
discovery sample size was reduced to match that of the TS sample (“Downsized OCD”), still 
detected a larger, and statistically significant, OCD polygenic signal than the comparable TS 
signal (p=0.01) (Figure 3, Table S3). The TS discovery sample was also too small to 
examine polygenic signals in TS subgroups (TS+OCD vs. TS-OCD); thus, it is possible that 
the TS polygenic signal could increase if “TS only” discovery and target samples were 
available. The TS polygenic signal may also have been attenuated by restricting polygenic 
risk score SNPs to those with MAF>5% (done to reduce bias due to undercalling of rare 
variants, see Supplementary Methods), as this class of SNPs has been shown to account for 
~20% of the variance in liability to TS, with 80% attributable to common variants (10). Both 
the investigation of TS subgroups and the analysis of polygenic signal including SNPs with 
MAF ≤ 5% may be possible in the future as the number of subjects with available GWAS 
data increases.
The cross-disorder polygenic analyses also provide evidence for genetic heterogeneity 
between OCD and TS. First, the polygenic risk scores generated from the individual OCD 
and TS discovery samples did not predict case-control status of the other disorder. Second, 
the combined TS/OCD sample was a worse predictor of OCD or TS status than either 
disorder alone, suggesting that the degree of genetic heterogeneity generated by combining 
the two phenotypes outweighs any improvement in statistical power due to increased sample 
size. As noted above, however, we are likely underpowered to detect a modest shared signal, 
which we have previously identified in this sample using a mixed-model approach (10).
Although we were not able to examine TS subgroups, we were able to examine the 
polygenic composition within OCD subgroups (i.e., OCD +/− TS/CT). These results clearly 
suggest that OCD with and without chronic tics have different genetic architectures. When 
OCD cases with co-occurring TS/CT were added to the OCD discovery sample, the 
polygenic signal in the independent OCD target sample was attenuated by 35% (permutation 
p=0.01), despite the 30% increase in sample size. Similarly, the risk score elevation between 
transmitted and untransmitted alleles dropped substantially with the addition of these 345 
OCD cases with TS/CT (p=0.022).
The hypothesis that OCD may be genetically heterogeneous, with some individuals and 
families segregating OCD without tics and others a subtype of OCD with tics that may share 
genetic risk with TS, was originally proposed by Pauls and colleagues in 1986 (27), and 
more recent epidemiologic studies have provided additional support for this concept (9, 26, 
28). Although not yet studied, these genetic differences may also correlate with well-
documented differences in treatment outcomes of patients with OCD alone compared to 
OCD with tics, in which the latter are more refractory to treatment and may require 
neuroleptic augmentation (29–31).
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Limitations
The primary limitation of this study relates to sample size. While our study represents the 
largest genetic sample of either disorder studied to date, the total sample of 3013 cases and 
5957 controls has 67% power to detect a disease variant with an odds ratio of 1.25 
(assuming risk allele frequency is 20% in the general population), and only 25% power to 
detect a variant with an odds ratio of 1.20. Recent studies of other psychiatric disorders with 
evidence of genetic overlap have required substantially larger sample sizes in order to detect 
individual variants that contribute to both disorders (32, 33). Therefore, caution is necessary 
when drawing conclusions about the genetic architecture of TS and OCD based exclusively 
on the results of the combined GWAS. However, we have more confidence in our 
interpretation of the polygenic analyses, where demonstrated significant differences between 
the aggregate polygenic risk for the TS/OCD phenotypes despite comparatively small 
sample sizes. Of note, aggregate polygenic signals have been successfully detected with a 
comparable number of subjects in other cross-disorder studies as well (32, 33).
In addition, although we propose that the differences in polygenic risk prediction between 
TS and OCD and between OCD with and without tics are due to divergent genetic 
architectures, alternative explanations should be considered, such as diagnostic 
misclassification or differences in case ascertainment between study sites or over time. It is 
also important to note that we focused on common variation, and that rare inherited 
variation, unique mutations within individual families, de novo mutations, structural 
variation and/or epigenetic and non-genetic factors are all likely contributors to the overall 
etiology of these related disorders. While our initial studies suggested that common variants 
account for most of the heritability of TS and OCD (10), it is still extremely important to 
explore all of these potential contributors to disease in order to acquire a full understanding 
of their relative contributions to TS and OCD.
Finally, interpretation of the eQTL/mQTL analyses are limited by the fact that the tissues 
analyzed represent a convenience sample based on currently available data, and thus, 
conclusions about tissue-specificity should be reserved until larger eQTL datasets across the 
full range of brain regions and developmental time periods are available.
Summary
Overall, our results argue that, in addition to some shared genetic variants contributing to 
susceptibility of either TS or OCD, genetic variants likely exist which provide phenotypic 
specificity for each disorder. This observation contrasts with the hypothesis that genes 
contributing to neuropsychiatric disorders provide a “generalist” framework of neuronal 
connections from which non-genetic factors determine specific phenotypes, as has been 
proposed to explain the wide range of phenotypes observed in patients with similar large 
recurrent CNVs across various regions of the genome (34, 35). Furthermore, the apparent 
difference between OCD with and without tics supports the importance of detailed 
phenotypic characterization to identify future subtype-specific risk alleles. Collection of 
additional samples through ongoing collaboration will be crucial to further elucidate the 
specific underlying susceptibility genes for TS and OCD, both shared and unique.
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FIGURE 1. Manhattan Plot of All Genotyped and Imputed Single-Nucleotide Polymorphisms 
for 3,013 Tourette’s Syndrome-Obsessive-Compulsive Disorder European Ancestry Cases and 
5,957 Controlsa
a
 Red and blue lines indicate significance thresholds of 5×10−8 and 1×10−5, respectively.
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FIGURE 2. Q-Q Plot of Nominal Disease Association p Values Versus Expected p Values Among 
the Cis eQTLs and mQTLs in Different Brain Tissues in the Tourette’s Syndrome, Obsessive-
Compulsive Disorder (OCD), and Combined Genome-Wide Association Study (GWAS)a
a
 eQTL=expression quantitative loci. A horizontal shift to the left from the diagonal line (of 
complete concordance between the observed p values and expected p values) in the Q-Q plot 
indicates enrichment.
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FIGURE 3. Individual Disorder and Cross-Disorder Polygenic Score Analysis in Tourette’s 
Syndrome and Obsessive-Compulsive Disorder (OCD)a
a
 The variance explained in two target samples (OCD European ancestry [EU] parent-child 
trios and Tourette’s French Canadian [FC] cases) is based on risk scores derived from an 
aggregated sum of weighted single-nucleotide polymorphism risk allele effect sizes 
estimated from discovery samples at six significance thresholds. The y axis indicates 
Nagelkerke’s pseudo R2. The p value under each discovery sample indicates how well the 
risk scores derived from the discovery sample can predict the illness phenotype in the target 
sample. N is the number of cases in each discovery sample. Negative R2 values indicate a 
negative correlation between risk scores and illness status in the target sample. OCD EU 
without known Tourette’s/chronic tics=European-ancestry OCD genome-wide association 
study (GWAS) samples after removing samples with known co-occurring Tourette’s/chronic 
tics; all OCD EU=European-ancestry OCD GWAS samples plus additional EU GWAS 
samples with co-occurring OCD and Tourette’s/chronic tics; combined Tourette’s/OCD 
EU=all European-ancestry Tourette’s GWAS samples and OCD GWAS samples; downsized 
OCD EU=randomly selected subset of OCD EU samples to match the number of cases in 
the Tourette’s EU discovery sample; Tourette’s EU=European-ancestry Tourette’s GWAS 
samples; OCD EU trios=the OCD EU parent-child trio probands and matched pseudo-
control data derived from nontransmitted alleles; Tourette’s FC=Tourette’s French Canadian 
cases and matching controls. A permutation test was carried out to determine the 
significance of the difference in R2 between risk scores derived from OCD EU without 
known Tourette’s/chronic tics and all OCD EU, resulting in a two-sided empirical p value of 
0.01. The inset box at upper right demonstrates the risk score elevations (difference in risk 
scores of transmitted alleles and untransmitted alleles in the OCD EU trios, standardized by 
the risk score of the untransmitted alleles) derived from three discovery samples: OCD EU 
without known Tourette’s/chronic tics, all OCD EU, and combined Tourette’s/OCD EU. 
Two-sided paired t tests were conducted for the pairwise comparisons of risk score 
elevations derived from three discovery samples.
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Table 2
Number of associated eQTLs/mQTLs with False Discovery Rate (FDR) <0.25 in the TS, OCD, and Combined 
GWAS eQTL, expression quantitative trait locus; mQTL, methylation quantitative trait locus;
Tissue Functional Subset
# of QTLs (# of loci*)
TS GWAS OCD GWAS Combined GWAS
Frontal Cortex eQTLs 0 (0) 0 (0) 0 (0)
Parietal Cortex eQTLs 0 (0) 0 (0) 53 (4)
Cerebellum eQTLs 38 (5) 0 (0) 0 (0)
Cerebellum mQTLs 0 (0) 161 (18) 0 (0)
*Number of LD-independent loci among the identified eQTLs.
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